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Clinical update on cancer: molecular oncology of head
and neck cancer
Y Suh1, I Amelio2, T Guerrero Urbano3 and M Tavassoli*,1
Head and neck cancers encompass a heterogeneous group of tumours that, in general, are biologically aggressive in nature.
These cancers remain difficult to treat and treatment can cause severe, long-term side effects. For patients who are not cured by
surgery and/or (chemo)radiotherapy, there are few effective treatment options. Targeted therapies and predictive biomarkers are
urgently needed in order to improve the management and minimise the treatment toxicity, and to allow selection of patients who
are likely to benefit from both nonselective and targeted therapies. This clinical update aims to provide an insight into the current
understanding of the molecular pathogenesis of the disease, and explores the novel therapies under development and in clinical
trials.
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Facts
 Head and neck squamous cell carcinoma (HNSCC) is the
sixth leading cause of cancer worldwide. Exposure to
carcinogens (tobacco and alcohol) and infection with
human papillomavirus (HPV) are the most common risk
factors.
 The main molecular determinants in HNSCC are the
abrogation of p53 and retinoblastoma (pRb) pathways that
lead to uncontrolled cell replication.
 Mutations in EGFR-MEK, NOTCH, PI3K, PTEN and AKT
pathways are frequently observed in HNSCC. These
mutations cooperate to create aberrant mitogenic/survival
signalling.
 Changes in metabolism and tumour hypoxia contri-
bute to resistance to current therapies and tumour
recurrence.
Open Questions
 Although HNSCC is a heterogeneous disease, the current
molecular classification distinguishes only HPV-positive
and HPV-negative tumours: further investigation to geneti-
cally classify HNSCC subgroups is needed.
 HNSCC metastasises primarily and frequently to regional
lymph nodes (more rarely to other organs via haemato-
genous spread): genetic profiles should aid the identifica-
tion of causative genes of metastasis.
 Radioresistance has been identified as an important cause
of locoregional treatment failure, and identification of
molecular mechanisms underpinning this could contribute
to better treatment selection and outcome.
 The genetics of HNSCC is complex, especially of HPV-
negative cancers: a detailed understanding of the mole-
cular basis and identification of driving mutations and
drugable targets should lead to personalised therapies.
Head and neck cancer accounts forB4% of all malignancies
worldwide and 5% mortality of all cancers,1 and includes the
following subsites: oral cavity, nasopharynx, oropharynx,
hypopharynx, larynx, paranasal sinuses, nasal cavity and
salivary glands. Over 90% are squamous cell carcinomas
(head and neck squamous cell carcinoma (HNSCC)), arising
from the epithelial cells that line the mucosal surfaces of the
head and neck.
More than 75% of cases of HNSCC are attributable to
smoking and alcohol consumption. Smoking increases the
risk by B10-fold compared with never smokers, and heavy
alcohol intake is an independent risk factor.2 The combined
effect of tobacco and alcohol causes a greater than multi-
plicative risk.3 Public health measures have been successful
in reducing the use of tobacco, and therefore the incidence of
HNSCC overall has been decreasing over the past 30 years in
developed countries. However, there has been a dramatic
increase in the incidence rates of oropharyngeal (tonsil and
base of tongue) cancers because of infection with high-risk
human papillomavirus (HPV).4,5
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At present, treatment of an individual cancer is typically
determined in a multidisciplinary setting, with the histological
subtype, subsite, staging information, patient fitness, baseline
swallow and airway function guiding management decisions.
Approximately one-third of patients present with early-stage
disease and these patients are treated with either surgery or
radiotherapy depending on the primary tumour site, with cure
rates of 70–90%.6 The majority of patients, however, present
with locally advanced stage disease. Radical treatment in this
situation requires multimodality therapy with surgery, com-
monly followed by postoperative radiotherapy or chemora-
diotherapy, or organ preserving primary radiotherapy, with or
without chemotherapy, with reduced cosmetic compromise.7
These treatments are intensive and associated with severe
acute toxicity, such as mucositis, dermatitis and dysphagia,
and long-term sequelae, for example, sensorineural hearing
loss, permanent xerostomia and altered swallowing function.
Despite recent advances in both surgical and radiotherapy
delivery techniques, up to 50% of locally advanced tumours
relapse usually within the first 2 years after treatment, with
limited options for salvage surgery or reirradiation.6,7 Several
chemotherapy agents can be used for inoperable recurrences
or metastatic disease, with response rates of only 10–35%
and median survival of 6–12 months.8
Beyond HPV status, no validated molecular characterisa-
tion of the disease has been established. However, pre-
liminary work suggests the existence of several different
molecular classes of HNSCC (basal, mesenchymal, atypical
and classical), based on the biological characteristics of
differentially expressed genes in each subtype.9 Genetic and
molecular advances have revealed new genes and pathways
involved in the development and progression of HNSCC,
creating opportunities to explore novel therapeutic targets.
HNSCC research has shifted to focus on biomarker discovery
for diagnosis, prognosis and prediction of treatment response,
alongside the development of targeted therapies, with the
ultimate goal of personalising therapy for each individual
patient.
TP53/RB Pathway
Tumour suppressor protein p53 plays a key role in the
regulation of genes involved in cell cycle and growth arrest,
DNA repair or apoptosis, thereby maintaining genomic
stability.10 In response to DNA damage, p53 can arrest the
cell cycle and activate repair or initiate apoptosis. p53 controls
a significant spectrum of genes involved in various path-
ways;11 these include recently discovered biochemical path-
ways, such as the connection of IL-7Ra to telomere erosion,12
the metabolism of the cell13 and the silencing of repeats and
noncoding RNA.14 This intense gene expression results in a
very fine regulation of life, death or senescence.15,16 p53 level
is regulated by mouse double minute 2 homolog (MDM2), an
E3 ubiquitin protein ligase that binds to p53 and causes its
degradation. MDM2 is inhibited by p14ARF that is encoded by
the gene CDKN2A, protecting p53 from degradation.10,17
Ataxia telangiectasia mutated (ATM) and ataxia telangiecta-
sia and Rad3-related (ATR) pathways sense DNA damage
and phosphorylate the cell cycle checkpoint kinases CHK1
and CHK2, resulting in p53 activation. p53 transactivates a
number of proteins with roles in cell cycle arrest and
apoptosis. Together with p53, its more recently discovered
family members, p63 and p73, have also been shown to play
important roles in cell cycle regulation and apoptosis, and their
link to various types of cancer including HNSCC is being
investigated.18
The tumour suppressor protein retinoblastoma (pRb)
controls the expression of genes involved in cell cycle
progression through the G1 restriction point. pRb binds and
inhibits E2F transcription factors that induce expression of
S-phase genes and cell proliferation. Mitogenic signals
activate cyclin D1/CDK4/CDK6 complexes that phosphorylate
pRb, resulting in the release of E2F. The cyclin D1-CDK4/6
complexes are inhibited by p16INK4A that is encoded by the
gene CDKN2A, and also p21 ((cyclin-dependent kinase
inhibitor 1 (CDKN1)) that binds to the complexes and prevents
them from phosphorylating pRb, thereby halting progression
into S phase.17
Mutations in p53 and pRb pathways result in limitless
replicative potential and immortalisation. TP53mutations can
occur throughout the entire gene but the majority are because
of a missense mutation in the DNA-binding domain. These
mutations can result in a number of consequences including
inhibition of function, tumour suppressor loss or occasionally
gain of function.19 Mutation of the TP53 tumour suppressor
gene is one of the earliest and most frequently detectable
genetic alterations in HNSCC reported in 50–80% of
cases,20,21 and can also be detected in premalignant
dysplastic lesions and in histopathologically negative tumour
surgical margins.22,23 A recent mutational screening in 12
types of cancer has revealed mutations of p53 in 69.8% of
HNSCC (Figure 1). From this analysis, HNSCC appears the
most common p53 mutation-carrying cancer type after
ovarian cancer and lung squamous cell carcinoma.24
Increased TP53 mutation rate is associated with tobacco
and alcohol use in HNSCC and also with increased risk of
progression to cancer.25,26 In p53 wild-type tumours, p53
function may be inactivated by other mechanisms, such as
HPV infection, overexpression or amplification of MDM2 and
deletion of the p14ARF gene.10
pRb is targeted early in the carcinogenesis of HNSCC
through inactivation of the tumour-suppressive CDKN2A
gene, with mutations seen in 7–9% and copy number losses
in a further 20–30% of cases.20,27 The CCND1 gene, which
encodes cyclin D1 on chromosome 11q13, is amplified or
overexpressed in over 80% of HNSCC.28 TP53mutation, loss
of p16INK4A and overexpression of cyclin D1 are all associated
with reduced survival.21,29 In addition, TP53 mutation is
predictive of poor response to chemotherapy and locoregional
recurrence following radiotherapy.30,31
Restoring or modulating p53 as targeted therapy has been
an area of intensive research for decades, with limited
success. Only one phase III study has been completed using
adenoviral p53 gene therapy in HNSCC. This showed that
patients with wild-type p53 had better response to Ad-p53
gene therapy, whereas mutant p53 patients responded better
to methotrexate chemotherapy, suggesting a potential of p53
profile as predictive biomarker of response to specific type of
therapy.32 p53-reactivating small molecules are currently
under investigation in HNSCC cell lines,33 and other
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strategies include targeting CDKN2A to reactivate p16INK4A
and CDK inhibitors. A phase I study of a CDK inhibitor in
combination with radiation has recently completed recruit-
ment (NCT00899054, Table 1).
Epidermal Growth Factor Receptor (EGFR) Pathway
EGFR (ErbB1) is a member of the ErbB/HER2 family of
transmembrane receptor tyrosine kinases. Other members
include HER2 (ErbB2), ErbB3 and ErbB4 and they play a
major role in cell proliferation, differentiation, survival and
migration. EGFR is composed of an extracellular ligand-
binding domain, a transmembrane segment and a cytoplasmic
domain with tyrosine kinase activity. It is activated by a
number of ligands including EGF, transforming growth factor-a
and amphiregulin. Ligand binding results in a conformational
change in EGFR and homo- or hetero-dimerisation with other
ErbB family members, leading to autophosphorylation and
receptor activation. This results in the activation of down-
stream signal transduction cascades including the Ras/Raf/
mitogen-activated protein kinase (MAPK), phosphoinositide
3-kinase (PI3K)/AKT and Janus kinase (JAK)/signal transdu-
cer and activator of transcription 3 (STAT3) pathways.34 The
EGF-bound EGFR can also translocate to the nucleus to
function as a transcription factor. One of the nuclear targets is
CCND1 that encodes cyclin D1 protein involved in cell cycle
progression (Figure 2).35
EGFR protein is detected by immunohistochemistry in over
90% of HNSCC cases. EGFR overexpression is mainly at the
transcriptional level as there are few EGFR-activating muta-
tions in HNSCC.36 Approximately 10–30% of HNSCC display
EGFR gene amplification, and EGFR point mutations are
reported in only 1–7% of patients.37,38 A mutant form of
EGFR, EGFRvIII, resulting from an in-frame deletion of exons
2–7 in the extracellular domain, has been reported in 42% of
HNSCC.39 The intensity of expression, as assessed by
immunohistochemistry, has been shown to indicate poor
prognosis, as has EGFR gene copy number.40,41 However,
the gene copy number has not been found to be a predictive
biomarker of efficacy with EGFR-directed therapy,41 unlike
specific mutations in non-small-cell lung cancer.
EGFR can be targeted either by inhibition of the extra-
cellular ligand binding using monoclonal antibodies (mAbs),
such as cetuximab, or by inhibition of the tyrosine kinase
domain with a small molecule (TKIs), such as gefitinib,
erlotinib and lapatinib. Cetuximab is a chimeric human–
murine IgG1 mAb directed specifically against EGFR, result-
ing in inhibition of cell cycle progression, angiogenesis and
metastasis, induction of apoptosis and synergy with radio-
therapy and chemotherapy. It remains the only FDA-approved
and European Medicines Agency-approved targeted therapy
in HNSCC and its use is not dependent on EGFR status. It is
used in combination with radiotherapy in locally advanced
HNSCC, in combination with platinum-based chemotherapy
and 5-fluorouracil for first-line treatment of recurrent/meta-
static disease, and as a single agent in recurrent/metastatic
disease after failure of platinum-based chemotherapy.42,43
Skin toxicity is a common side effect with cetuximab treatment
and this clinical feature has been suggested as a biomarker
for response to cetuximab, with response rates of 33%
observed in patients with skin rash compared with 7% in those
who do not develop skin toxicities.44 Panitumumab is a fully
humanised mAb against EGFR in use in colorectal cancer.
In HNSCC, a phase III trial of panitumumab in combination
with chemotherapy did not show an improvement in survival,
although retrospective analysis showed that median overall
survival in p16 (surrogate marker for HPV)-negative patients
was longer in the panitumumab group than in the control
group.45 Other promising mAbs currently in phase III trials
include zalutumumab and nimotuzumab (NTC00496652 and
NTC00957086). Despite the high expression of EGFR in
HNSCC, EGFR inhibition with mAbs has only a modest effect.
Preclinical studies investigating resistance to EGFR inhibition
have suggested mechanisms such as increased nuclear
localisation of EGFR, cross-talk of EGFR with other receptor
tyrosine kinases, such as HER2 and ErbB3, as well as
upregulation of these receptors and their ligands.46
TKIs block the activation and phosphorylation of EGFR, and
these drugs are given orally as they are well absorbed across
the gastrointestinal tract. Gefitinib and erlotinib, currently used
in lung cancer, inhibit only EGFR and have not been shown to
be efficacious in HNSCC to date. Because of the potential
resistance mechanisms, TKIs that have action against multi-
ple ErbB family receptors are under investigation. Lapatinib
has dual specificity for EGFR and HER2 and is in use in
breast cancer. In HNSCC trials, it has shown activity in
p16-negative tumours in combination with chemoradiation,47
and is currently being evaluated in the recurrent/metastatic
setting in combination with capecitabine chemotherapy
(NCT01044433), and in a phase III adjuvant trial (NCT
00424255). Afatinib irreversibly blocks EGFR, HER2 and
ErbB4 and is being investigated in the recurrent/metastatic,
neoadjuvant and adjuvant settings (NCT 01856478,
NCT01538381 and NCT01345669).
NOTCH Pathway
NOTCH1 signalling is involved in a number of biological
functions, including regulation of self-renewal capacity,
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Figure 1 The p53 structure with different protein domains (transactivation
domain, proline-rich domain, DNA-binding domain, oligomerisation domain and
regulation domain). Vertical lines indicate the occurrence of mutation of the amino
acid residues in HNSCC (data from COSMIC website: cancer.sanger.ac.uk/
cancergenome/projects/cosmic)
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survival and promoting terminal differentiation. The NOTCH
pathways consist of four receptors bound to the cell
membrane, NOTCH 1–4, and two families of ligands, Delta-
like (1, 3 and 4) and Jagged (1 and 2). Ligand binding leads to
two cleavages of NOTCH1 by TNFa-converting enzyme
(TACE) and g-secretase, resulting in the release of NOTCH1
intracellular domain (NCID). NCID translocates to the nucleus
to promote transcription of its target genes, including the HRT
and HES families. NOTCH1 is regulated partly by ubiquitina-
tion and degradation that involves FBXW7.48
One of the novel findings generated from whole-exome
sequencing was the discovery that the second most common
mutation in HNSCC is in the NOTCH1 gene, accounting for
14–15%, with mutations in the other NOTCH family members
occurring in 3–5% of HNSCC.20,27 Mutations in the FBXW7
gene were also identified in 5% of cases that have not been
previously observed in HNSCC.20 Recent integrated analysis
has identified the NOTCH pathway to be defective in 66% of
HNSCC patients. Along with the mutations in NOTCH itself,
chromosomal aberrations were frequent in JAG1, JAG2,
MUMB and MAML1, all of which are involved in modulating
NOTCH signalling.49 NOTCH1 signalling has been reported to
be oncogenic, as activating mutations and translocations
were found in NOTCH receptor genes in haematological
malignancies.50 However, in HNSCC, the majority were
nonsensemutations, predicted to result in truncated NOTCH1
proteins lacking the transcriptional activation domains, there-
fore suggesting a tumour-suppressor role for this pathway in
HNSCC.
NOTCH1 signalling promotes terminal differentiation in
keratinocytes and skin SCC, and this is negatively regulated
by EGFR. Inhibition of EGFR blockade induces keratinocyte
Table 1 Targeted therapies in HNSCC
Type of drug Drug Target Stage of development NCT number
Adenovirus gene therapy Advexin p53 Phase III NCT00064103
ONYX-015 p53 Approved in China N/A
CDK inhibitor P276-00 pRb Phase II NCT0089954
Monoclonal antibody Cetuximab EGFR In clinical use N/A
Panitumumab Phase II NCT00756444
NCT00454779
NCT00820248
Zalutumumab Phase III NCT00496652
Nimotuzumab Phase III NCT00957086
Bevacizumab VEGFR Phase II NCT01588431
Tyrosine kinase inhibitor Gefitinib EGFR Phase III NCT00206219
NCT00684385
Erlotinib EGFR Phase II NCT01064479
Lapatinib EGFR, HER2 Phase III NCT00424255
Afatinib EGFR, HER2, ErbB4 Phase III NCT01856478
NCT01345669
NCT01345682
Sorafenib VEGFR-2, VEGFR-3, Raf, PDGFR Phase II NCT00939627
Sunitinib VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, RET, c-KIT Phase II NCT00387335
Vandetanib EGFR, VEGFR, RET Phase II NCT00459043
Pazopanib VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, c-KIT Phase II NCT01377298
Axitinib VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, c-KIT Phase II NCT01469546
Nilotinib BCR-ABL, c-KIT, PDGFR Phase I NCT01871311
MEK inhibitor Trametinib MEK Phase I NCT01725100
PI3K inhibitor PX866 PI3K Phase II NCT01204099
BKM120 PI3K Phase II NCT01527877
BYL719 PI3K Phase II NCT01602315
Rigosertib PI3K, PLK Phase II NCT01807546
AKT inhibitor MK2206 AKT Phase II NCT01349933
mTOR inhibitor Rapamycin mTOR Phase II NCT01195922
Everolimus mTOR Phase II NCT01133678
Temsirolimus mTOR Phase II NCT01172769
CC-115 mTOR, DNA-PK Phase I NCT01353625
JAK inhibitor Ruxolitinib JAK Phase I NCT04822756
MET/VEGFR inhibitor Foretinib MET, VEGFR-2 Phase II NCT00725764
E7050/Golvatinib MET, VEGFR-2 Phase II NCT01332266
MET inhibitor LY2801653 MET Phase I NCT01285037
PDK inhibitor Dichloroacetate PDK Phase I NCT01386632
AMPK activator Metformin AMPK Phase II NCT01333852
Data source: www.clinicaltrials.gov
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differentiation.51 NOTCH1 has also been found to be inhibited
in basal epithelial cells by the p53-related transcription factor
p63 that becomes downregulated during terminal differentia-
tion coinciding with NOTCH1 upregulation. Overexpression
and amplification of TP63 have been observed in the majority
of HNSCC.52 However, as p63 encodes several isoforms with
opposing functions, the precise role of p63 in NOTCH1
signalling and malignant transformation of oral epithelial cells
remains to be elucidated.
NOTCH1 signalling has also been linked to suppression of
HPV E6 and E7 protein expression in cervical carcinoma cell
lines; expression of activated NOTCH1 causes growth
inhibition of HPV-positive but not HPV-negative cervical
carcinoma cell lines, and results in the downmodulation of
HPV-driven transcription of the E6 and E7 viral genes.53 The
role of NOTCH1 in the complex signalling pathway of HNSCC
tumourigenesis needs to be further investigated, but could
potentially represent another therapeutic target. Both
NOTCH1 pathway inhibitors that inhibit g-secretase and
NOTCH1 pathway activators, via inhibition of histone deace-
tylase, are currently in clinical development.
PI3K/AKT/mTOR Pathway
PI3Ks are a family of enzymes that phosphorylate the 30OH
position of phosphatidylinositols and have important roles in
promoting cell growth, differentiation and survival. There are
three classes of PI3Ks, each with its own substrate specificity,
and class 1A is most frequently associated with cancer. Class
1A PI3Ks are heterodimers and composed of a 110-kDa
catalytic subunit and an 85-kDa regulatory subunit, both of
which exist in several isoforms. PI3Ks are activated by RTKs,
such as EGFR, and the catalytic subunit phosphorylates
phosphatidylinositol1,4-bisphosphate (PIP2) to form phos-
phatidylinositol1,4,5-triphosphate (PIP3). PIP3 recruits pleck-
strin-homology domain-containing proteins including
phosphoinositide-dependent protein-kinase 1 (PDK1) and
AKT to the plasma membrane. Interaction of PIP3 with the PH
(Pleckstrin Homology) domain of AKT results in a conforma-
tional change causing phosphorylation of AKT by PKD1 and
mammalian target of rapamycin complex 2 (mTORC2). This
activates AKT that then phosphorylates proteins involved in
cell growth and survival. The tumour-suppressor phosphatase
and tensin homology (PTEN) mediates the conversion of PIP3
to PIP2, counteracting the activation of AKT.
54 mTOR is a
protein kinase that acts downstream of PI3K and AKT and
plays an important role in cell growth, survival and protein
synthesis regulation. There are two mTOR complexes:
mTORC1 activates ribosomal protein S6 kinase 1 (SK6) and
inactivates eukaryotic translation initiation factor 4E-binding
protein 1 (4E-BP1), resulting in protein translation and cell
growth, whereas mTORC2 activates AKT.
Genetic aberrations of the PI3K pathway are common in
HNSCC. One of the isoforms of the 110 kDa catalytic subunit,
p110a, is encoded by the PIK3CA gene. This gene is mutated
in 6–20% of HNSCC, especially through the mechanisms of
gene amplification and low-level copy number increase.20,27
It has been found to be particularly common in HPV-positive
HNSCC cases, and specific mutations, such as H1047R in
exon 20, may predict higher response rates to treatment with
PI3K pathway inhibitors.55,56 In addition, PTEN mutations
have been reported in 7% of HNSCC, and themTOR pathway
is frequently activated, independent from activation of EGFR
or the presence of mutant p53, particularly in HPV-positive
tumours.27,57
PI3K pathway is an important therapeutic target for cancers
and its therapeutic modulation has been assessed in a number
of tumour types. The mTOR inhibitor everolimus is in clinical
use in renal cell carcinoma, pancreatic neuroendocrine
tumours, breast cancer and subependymal giant cell astro-
cytoma, and temsirolimus can be used in renal cell carcinoma.
PI3K inhibitors are being investigated in phase II trials in
HNSCC in conjunction with chemotherapy or cetuximab
(NCT01252628); AKT inhibitors are being tested in recurrent
ormetastatic nasopharyngeal cancer (NCT01349933); and the
mTOR inhibitors rapamycin, everolimus and temsirolimus are
being assessed for HNSCC at the phase II stage in
neoadjuvant and recurrent/metastatic settings.
Ras/Raf/MEK/MAPK Pathway
Ras is a guanosine nucleotide binding protein localised on the
plasma membrane. There are three Ras genes: HRAS, KRAS
and NRAS. In the inactivated state, Ras is bound to guanosine
diphosphate (GDP) and activation converts Ras to the
guanosine triphosphate (GTP)-bound form; Ras-GTP binds to
and activates Raf-1. The targets for phosphorylation of Raf-1
include the kinases MEK1 and MEK2 that in turn activate the
MAPkinasesERK1andERK2. These translocate to the nucleus
and target genes involved in cell growth, proliferation and
survival. Ras can also activate the PI3K signalling cascade.58
Mutations in the Ras proto-oncogenes are implicated in
20–30% of all cancers.58 Activating HRAS mutations have
been found in 4–5% of HNSCC cases.20,27 KRAS mutations
occur in 30–50% of colorectal cancers and are predictive
of poor response to panitumumab and cetuximab.59
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Figure 2 Schematic representation of the major molecular pathways affected in
HNSCC. Stars indicate possible mutations in the molecule. EGFR, MET and
NOTCH activation can promote molecular signalling through RAS/ERK, PI3K/AKT
or JAK/STAT pathways. Aberrant activation of these pathways promotes survival,
proliferation and motility of cancer cells, favouring HNSCC tumourigenesis
Head and neck cancer
Y Suh et al
5
Cell Death and Disease
The predictive value of KRAS in HNSCC remains unclear and
requires further investigation.
Sorafenib is a tyrosine kinase inhibitor that has multiple
targets including Raf, VEGF (vascular endothelial growth
factor receptor) and PDGFR (platelet-derived growth factor
receptor).60 It is in use in renal cell carcinoma and
hepatocellular carcinoma, but has poor results as a single
agent in HNSCC. Sorafenib in combination with chemother-
apy has shown a response rate of 55% and median overall
survival of 22.6 months in a phase II trial in HNSCC.61 The
MEK inhibitor trametinib has recently been approved for use in
metastatic melanoma and is under investigation in combina-
tion with AKT inhibition in solid tumours including HNSCC
(NCT01725100).
MET Pathway
The proto-oncogene c-MET encodes mesenchymal–
epithelial transition factor (MET), an RTK activated by
hepatocyte growth factor (HGF). Ligand binging activates
signalling cascades including the RAS, PI3K, STAT3 and
NOTCH pathways, resulting in cell morphogenesis, motility,
growth and survival. MET and HGF have been found to be
overexpressed in over 80% of HNSCC and increased MET
copy numbers in 13% of HNSCC tumour samples.62,63 MET
expression has been suggested to be a prognostic biomarker
in HPV-negative HNSCCwith overexpression correlating with
reduced disease-free and overall survival.64,65 It has also
been implicated in resistance to radiation, cisplatin and
cetuximab.66–68
MET overexpression results in enhanced cell motility,
angiogenesis and invasion/metastases, and therefore is an
important potential therapeutic target. Foretinib is a multi-
tyrosine kinase inhibitor that binds to the adenosine tripho-
sphate (ATP) pocket of the receptor. It has been tested in a
phase II study in recurrent/metastatic HNSCC but showed
disease stabilisation and only minor tumour shrinkage as a
single agent.69 There are several RTK inhibitors and mAbs
against MET and HGF in early phase clinical trials.
JAK/STAT Pathway
The JAKs are part of a family of nonreceptor tyrosine kinases.
They interact with the cell surface cytokine receptors and
activate them by transphosphorylation. Activated cytokine
receptors recruit STAT that is phosphorylated by JAKs,
mediating dimerisation and translocation to the nucleus to
activate transcription of their target genes. JAKs can also be
phosphorylated directly by RTKs such as EGFR, activating
the RAS and PI3K pathways. The JAK/STAT pathway has a
role in promoting cell growth and survival, angiogenesis and
suppression of immune surveillance.70
STAT proteins are important in mediating EGFR signalling
and STAT3 is overexpressed in HNSCC.71 Ruxolitinib is a
JAK inhibitor approved for use in myelofibrosis and is in phase
I studies in combination with chemotherapy in advanced solid
tumours. A phase 0 trial of a STAT decoy oligonucleotide
injected into HNSCC tumours before surgery demonstrated
downregulation of STAT3 target gene expression, warranting
further investigation of this target in HNSCC.72
HPV-Mediated Pathogenesis
HPVs are small, nonenveloped, double-stranded DNA
viruses. The genome encodes for early genes (E1–7) and
late structural genes (L1, L2). E1 and E2 encode regulatory
proteins and E5–7 encode oncoproteins. Over 100 human
HPV genotypes have been isolated, and mucosal HPVs can
be classified into high and low risk based on their potential to
induce malignant transformation. High-risk HPVs include
types 16, 18, 31 and 33, with HPV type 16 accounting for
over 90% of cases in HNSCC.73 HPVs enter the host via
wounds or abrasions in the mucosa and infect basal epithelial
cells, where the host cell DNA replication machinery is used
for viral replication. The basal cell nuclei maintain low copy
numbers of viral DNA, whereas the virus replicates to high
copy numbers in terminally differentiated cells.74 The E6
protein interacts with E6-associated protein (E6-AP), resulting
in a rapid degradation of tumour suppressor p53 via the
ubiquitin–proteosome pathway (Figure 3). This leads to
inhibition of the proapoptotic functions of p53 and bypassing
of the p53-mediated checkpoints.75 The E7 protein competes
with E2F transcription factor for binding to the pRb tumour
suppressor, displacing E2F. E2F activates genes responsible
for cell cycle progression through the G1 to S phase, including
cyclin A, E and DNA polymerase, causing inactivation of
checkpoints and regulatory pathways, and ultimately promot-
ing cellular proliferation and transformation (Figure 3).76 pRb
is a negative regulator of the cyclin-dependent kinase inhibitor
p16, and therefore inactivation of pRb results in p16
upregulation. This can be detected using immunohistochem-
istry in HPV-associated tumour samples and represents a
biologically significant surrogate marker for HPV oncoprotein
expression.77
G1
E2F
E2F
RB
RB
P
P
P
CDK2CycE
p21
p53
p53
HPV
HPV
RB
HPV
E7
E6
S
G2
M
CDK4/6CycD1
p16
RB
Figure 3 Mechanism of action of the human papillomavirus (HPV) on cell cycle
regulation. To progress from G1 to S cell cycle phase, cells have to pass the G1
restriction point that is under the control of the retinoblastoma protein (pRb). pRb
binds and represses E2F transcriptional factors. Mitogenic signalling through
CyclinD1/CDK4 or CyclinD1/CDK6 phosphorylates pRb, promoting E2F release.
CyclinE/CDK2 completes pRb phosphorylation, allowing S-phase entry. HPV
affects the cell cycle by using two viral oncoproteins, E6 and E7. The E6 protein
binds p53 and promotes its degradation, whereas E7 protein binds and inactivates
pRb. These viral oncoproteins determine cell cycle entry and inhibition of p53-
mediated apoptosis. HPV-dependent inhibition of pRb promotes p16 accumulation.
p16 represents a surrogate marker of HPV-positive HNSCC
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HPV infection in oropharyngeal cancer is now recognised
as an aetiological agent, responsible for the significant
increase in incidence in Western countries (Table 2).5,78
These cancers represent a distinct subgroup characterised by
specific biological and clinical profiles and improved out-
comes. Patients with HPV-associated oropharyngeal squa-
mous cell carcinoma (OPSCC) tend to be white males, on
average 5 years younger than HPV-negative patients, have
higher socioeconomic status and are less likely to smoke or
drink alcohol.4 Risk factors for HPV-positive HNSCC are
related to sexual behaviour, including young age at first
intercourse and high number of sexual partners, in particular
oral sex partners, and antibodies against HPV16 viral capsid
protein and E6 oncoprotein.79–82 Clinically, these tumours
have been found to be present at an earlier stage of the
primary cancer but with cystic, multilevel nodal metas-
tases.83,84 Histologically, the tumours tend to be poorly
differentiated basaloid (or nonkeratinising squamous cell)
carcinomas.85 HPV is detected in other subsites such as
larynx and nasopharynx but no causal relationship or
association with outcome has been established, and therefore
the significance in nonoropharyngeal head and neck tumours
remains unclear.86
HPV-associated OPSCC has a favourable prognosis.
Compared with HPV-negative OPSCC, patients have a
60–80% reduction in the risk of death from their cancer after
controlling for other factors, highlighting the need for different
treatment strategies to reduce the morbidity associated with
current treatment.77,78 The reasons for the improved outcome
are unclear but possibilities include host factors such as
younger age, fewer smoking-related comorbidities and
tumour factors such as increased sensitivity to radiotherapy,
absence of field cancerisation mainly seen in smokers,
differing response of the host immune system to viral
infection, and the presence of wild-type p53 that may become
activated in response to radiotherapy and chemotherapy.
However, not all HPV-positive patients have the same
excellent outcome and they can be further classified into low
and intermediate risk of death categories depending on their
smoking history.87 HPV-negative HNSCC are typically char-
acterised by TP53 and RB genetic alterations resulting in
genomic instability and resistance to apoptosis. No TP53
mutations were seen in HPV-positive HNSCC on exome
sequencing, and the overall mutation rate was approximately
half of that seen in HPV-negative samples. In addition, in
contrast to HPV-negative tumours, the expression of
CDKN2A, encoding p16INK4A, is highly upregulated and
amplification of cyclin D is infrequent.88
At present, treatment is the same regardless of HPV status
outside the context of a clinical trial. Two phase III studies
currently recruiting (De-ESCaLATE HPV and RTOG 1016)
are investigating the replacement of standard cisplatin in
concomitant chemoradiation with cetuximab, on the basis that
cetuximab may be less toxic with comparable results in
retrospective analyses.89 The results of two studies treating
HPV-positive patients with induction chemotherapy followed
by reduced dose radiation in responders are awaited. HPV
vaccines are under development and investigation, as both
preventative and therapeutic applications. Gardasil and
Cervarix are HPV vaccines in use for the prevention of
cervical cancer, but could afford protection against oral
HPV16/18 infection. Reduced prevalence of oral HPV
infection was found in women recruited to investigate the
efficacy of HPV vaccination against cervical cancer.90 These
vaccines may also cause induction of cell-mediated immunity
against HPV-positive tumours, and phase I studies are
ongoing investigating the use of HPV16 peptide epitopes in
recurrent disease.91
Hypoxia and Angiogenesis
Tumour hypoxia is common in HNSCC and is associated with
treatment resistance and reduced survival.92 Under normoxia,
the hypoxia-inducible factors HIF1-a and HIF2-a are rapidly
degraded by the Von Hippel–Lindau protein (VHL). Hypoxia
leads to stabilisation of HIFs that heterodimerise with
constitutively expressed HIF2b and translocate to the
nucleus. Genes that promote survival in hypoxia, including
carbonic anhydrase 9 (CA9), glucose transporter 1 (GLUT1)
and vascular endothelial growth factor (VEGF), are upregu-
lated. HIF2-amediates activation of EGFR, and HIF activation
is partly regulated by mTOR signalling.93 Hypoxia can also
drive genomic instability in tumour cells and select for cell
populations with a more aggressive phenotype, reduced
apoptotic and increased metastatic potential.94
Oxygen is required for effective radiation-induced cell
damage, as oxygen stabilises the free radicals produced by
ionising radiation that causes DNA damage and cell death.95
To improve their nutrient and oxygen supply, tumours produce
angiogenic factors that induce the proliferation of endothelial
cells and form new blood vessels. VEGF is the strongest inducer
of angiogenesis, and immunohistochemical expression in
tumour samples is associated with an increased risk of death.96
Strategies to improve tumour oxygenation have included
the use of hyperbaric oxygen, carbogen and nicotinamide,
radiosensitisation using nitroimidazoles and the hypoxic
cytotoxin tirapazamine. However, because of the difficulties
in measuring and stratifying for hypoxia, these techniques
have not translated into regular clinical practice.95 There is
therefore interest in developing methods to diagnose hypoxia
and predict the response to hypoxia-modifying treatments.
For example, a 15-gene hypoxia classifier applied retro-
spectively to HNSCC tissue samples was found to predict for
hypoxic modification of radiotherapy with the radiosensitiser
nimorazole.97 More recently, a 26-gene hypoxia signature
showed predictive benefit from hypoxia-modifying agents
carbogen and nicotinamide in combination with accelerated
radiotherapy.98 Prospective application and validation of
these signatures are awaited. The VEGFR-targeting thera-
pies are currently under investigation in HNSCC.
Table 2 Clinical features of HPV-positive and -negative HNSCC
HPV negative HPV positive References
Aetiology Tobacco/alcohol HPV infection 2,5,78
Age Above 60 years Below 60 years 5
p53 mutations Highly frequent Infrequent 20,27
Site Not predictable Oropharynx 78
Prognosis Poor Favourable 77,87
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Bevacizumab, a monocloncal antibody against VEGFR, is in
clinical use in metastatic colorectal and breast cancer,
NSCLC, glioblastoma and renal cell carcinoma. Phase II
studies in HNSCC using bevacizumab in combination with
pemetrexed, erlotinib or cetuximab have shown response
rates of 15–30%.99–101 The multiple tyrosine kinase inhibitors
sunitinib, sorafenib and vandetanib are in clinical use, and
sorafenib has shown promise in combination with chemother-
apy in recurrent/metastatic HNSCC (Table 1).
Metabolism
Energy in the form of ATP is generated in normal cells via
glycolysis or the tricarboxylic acid (TCA) cycle. In glycolysis,
glucose is metabolised to pyruvate in the cytosol to produce
two ATPs from each molecule of glucose. The TCA cycle
utilises pyruvate from glycolysis to produce acetyl-CoA that is
catalysed by pyruvate dehydrogenase (PDH) in the mitochon-
dria. Acetyl-CoA is metabolised by oxidative phosphorylation,
consuming oxygen and generating 36 ATPs per glucose. In
anaerobic conditions, pyruvate is not used in the TCA cycle
and is converted to lactate in the cytosol by lactate
dehydrogenase (LDH).102
Metabolic alterations are common in cancer. The best-
characterised metabolic phenotype was originally described by
Warburg et al.103 in the 1920s. The Warburg effect is the
increase in glycolysis to generate ATP, even in the presence of
normal oxygen concentrations. ATP production via glycolysis is
much faster but less efficient than oxidative phosphorylation,
and cancer cells avidly consume glucose to meet their
increased energy and biosynthesis needs.104 Aerobic glyco-
lysis in tumour cells is regulated by aberrant signalling
pathways, including p53, PI3K, HIF1, MYC105–107 and liver
kinase B1 (LKB1)/AMP-activated protein kinase (AMPK) path-
ways,108 as well as alterations in metabolic enzymes, such as
pyruvate kinase and pyruvate dehydrogenase kinase (PDK).109
Aberrant metabolism can be targeted by inhibiting the AKT
and mTOR pathways as previously discussed. PDK inhibition
with dichloroacetate is being explored in a phase I trial of
metabolic reprogramming therapy in recurrent HNSCC
(NCT01163487). Metformin is currently used in type II
diabetes but also acts as an AMPK activator. Diabetic patients
treated with metformin were found to be at lower risk of
developing cancer than those on other treatments.110
Metformin in combination with paclitaxel is being investi-
gated in a phase II trial in metastatic/recurrent HNSCC
(NCT01333852).
HNSCC Cancer Stem Cells
HNSCC is highly heterogeneous. This heterogeneity was
originally thought to be because of the step-wise accumulation
of specific genetic and epigenetic alterations in response to
carcinogens, resulting in preneoplastic fields. Clonal diver-
gence and selection within these fields leads to the develop-
ment of cancer, and the incomplete eradication of these areas
are the source of recurrence and secondary tumours after
treatment.111 However, accumulating evidence supports an
alternative model for the development and progression of
HNSCC involving cancer stem cells (CSCs). This model
describes the existence of a hierarchy of cells, where CSCs
are a subpopulation within the tumour, capable of initiating
and propagating tumourigenesis. These cells have the ability
of self-renewal, maintaining the CSC reservoir and differenti-
ate into the heterogeneous progeny.112 CSCs have been
implicated in resistance to treatment, as they are nondividing
or slowly dividing, evading the conventional chemotherapy
and radiotherapy strategies that target rapidly diving cells.113
However, they have the potential to become activated
resulting in recurrences or metastases.
CD44 is a transmembrane glycoprotein that acts as a receptor
for hyaluronic acid and other extracellularmatrixmolecules, and is
involved in cell adhesion andmigration. Alternative splicing results
in multiple different CD44 variants with a diverse functional
repertoire.114 HNSCCCSCswere first described based on CD44
expression.115 CD44þ HNSCC cells, but not CD44 cells,
initiated tumourigenesis in mice, reproduced the original tumour
heterogeneity and demonstrated self-renewal after serial
passaging in vivo.115 CD44þ cells were also found to
differentially express the BMI-1 gene,115 encoding a self-renewal
protein found in embryonic stem cells.116 However, expression of
CD44 has also been observed diffusely in normal, benign and
malignant epithelia of the head and neck, suggesting CD44 alone
cannot identify CSCs.117
Aldehyde dehydrogenase (ALDH) is an enzyme involved in
detoxifying intracellular aldehydes by oxidation, and convert-
ing retinol to retinoic acid.118 It has been shown that ALDHþ
and CD44þ cells form a subpopulation of cells that are highly
tumourigenic in immunodeficient mice at very low cell
numbers, as well as the ability to self-renew.119 Therefore,
the combination of these two markers are more selective for
CSCs. ALDH1þCD44þ cells have also demonstrated
increased expression of BMI-1,119 resistance to chemoradia-
tion and involvement in epithelial–mesenchymal transition.120
CSCs represent potential novel diagnostic and therapeutic
targets. The concentration of CD44 in the peripheral blood of
HNSCC patients has been shown to be significantly higher
than healthy controls,121 and increased CD44þ cell popula-
tion in the primary tumour correlates with higher rates of
recurrence.122 In addition, CD44 gene expression levels have
been found to correlate with response to radiotherapy in
laryngeal SCC, suggesting its role as a predictive marker.123
Targeted elimination of cancer stem cells directly or via their
niche, for example, with antiangiogenic agents, are potential
treatment strategies under development. Bivatuzumab mer-
tansine, an anti-microtubule agent coupled to a monoclonal
antibody against CD44 variant 6, has been tested in
metastatic HNSCC. However, two parallel phase I studies
were terminated early after a fatal case of toxic epidermal
necrolysis.124 Further investigation is required to fully under-
stand the potential effects of targeting CSCs in HNSCC.
Gene and MicroRNA Expression in HNSCC
There has been a multitude of published studies investigating
gene expression profiling to diagnose HNSCC and predict
behaviour and sensitivity to treatment.125–127 The detailed
analysis of such studies is beyond the scope of this review; in
general, because of tumour heterogeneity and low case
numbers in some studies, these studies have not been
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conclusive. Larger and heterogeneous patient cohorts are
therefore needed to obtain an mRNA signature that can be
utilised in a clinical setting.
MicroRNAs (miRNAs) are endogenous, small, non-coding
RNAs of 18–25 nucleotides that regulate and refine gene
expression at both transcriptional and translational levels.
Over 1000 miRNAs have so far been identified, with each
miRNA influencing the expression of multiple genes and a
single mRNA being targeted by several miRNAs. They are
involved in the fine-tuning of the expression of many genes
involved in a variety of critical biological processes, including
cell cycle regulation, differentiation, metabolism and death
(Table 3).128 Consistently altered miRNAs in HNSCC include
miR-21 that is negatively correlated with PTEN and the
programmed cell death 4 (PDCD4) gene and implicated in cell
proliferation, invasion and metastases;129 the miR-106b
family that negatively regulates the p21 CDK inhibitor;130
and miR-205 that targets PTEN and is suggested as a
potential maker for diagnosis, lymph mode metastasis and
outcome.131,132 The ratio of miR-221 to miR-375 can
distinguish between normal and malignant tissue,133 and high
expression of miR-181 and miR-211 in oral SCC has been
found to be associated with lymph node metastases, vascular
invasion and poor outcome.134,135 Tumour-suppressive miR-
NAs include let-7 that negatively regulates KRAS, and
reduced expression is associated with poor prognosis.131,136
MiR-133a/b is repeatedly reported to be downregulated in
HNSCC and targets pyruvate kinase M2, a key regulator of
cancer metabolism.137 MiR-133a also directly regulates the
actin-related protein complex 5 (ARPC5) with inhibition of cell
migration and invasion when miR-133a is restored or ARPC5
is repressed.138 Downregulation of the tumour-suppressive
miR-200a is seen in both saliva and tissue samples of HNSCC
patients and is known to target ZEB1 and ZEB2 that repress
the transcription of E-cadherin and mediate epithelial–
mesenchymal transition and tumour cell migration.139 MiRNAs
are also implicated in chemoresistance, with different patterns
of expression in resistant HNSCC.140 Modulation of miRNAs
can alter the sensitivity of HNSCC to both drugs and radiation,
highlighting the potential for miRNAs in predicting response to
treatment and as a therapeutic target.
Conclusion
HNSCC is a group of highly heterogeneous tumours. Their
management is likely to change in the near future, moving
from treatment as a single disease to tailoring the therapy
based on both patient and tumour characteristics. Identifica-
tion of specific genetic, epigenetic and metabolic aberrations,
together with the more traditional techniques in diagnosis,
staging and prognostication, will need to inform the individual
treatment strategy. It has the potential to provide the clinician
with a comprehensive set of diagnostic, prognostic and
predictive tools. The paucity of driver mutations in HNSCC
and frequent tumour suppressor loss represents a pharma-
cological challenge, but increased understanding of the
molecular biology through the developments in high-through-
put technology heralds a future of personalised medicine.
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